Genprex
GNPX
21 hedge funds and large institutions have $10.8M invested in Genprex in 2022 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 7 closing their positions.
173% more call options, than puts
Call options by funds: $1.5M | Put options by funds: $549K
11% more capital invested
Capital invested by funds: $9.78M → $10.8M (+$1.06M)
0% less ownership
Funds ownership: 0% → 0% (-0%)
16% less funds holding
Funds holding: 25 → 21 (-4)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
57% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$195K |
| 2 |
Charles Schwab
San Francisco,
California
|
+$97.5K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$97.5K |
| 4 |
Group One Trading
Chicago,
Illinois
|
+$97.5K |
| 5 |
State Street
Boston,
Massachusetts
|
+$97.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$1.85M |
| 2 |
Renaissance Technologies
New York
|
-$1.18M |
| 3 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$575K |
| 4 |
Millennium Management
New York
|
-$488K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$390K |
GNPX Hedge Fund Activity: Q1 2022 in Review
21 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Genprex (GNPX) for Q1 2022, worth a combined $10.8M — up 11% from $9.78M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of GNPX and 3 opened new positions — a net loss of 4 holders — while 4 trimmed existing stakes and 3 added.
The largest buyer was Goldman Sachs, adding an estimated $195K. The largest seller was Morgan Stanley, cutting an estimated $1.85M.
- 21 institutional investors held Genprex (GNPX) as of Q1 2022, down from 25 in Q4 2021.
- Funds reported $10.8M of Genprex stock for Q1 2022, up 11% quarter-over-quarter.
- 3 funds opened new Genprex positions in Q1 2022 and 7 closed out, a net change of -4 holders.
- The largest Genprex buyer in Q1 2022 was Goldman Sachs, an estimated $195K added.
- The largest Genprex seller in Q1 2022 was Morgan Stanley, an estimated $1.85M sold.
Based on aggregated 13F filings for Q1 2022.